Physician profile
Mandeep Kataria
NPI 1174105837
$499.32
in general payments reported to CMS, 2019-2025
13 companies · $440 in 2025
The $440 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $59.19 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $499.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $95.15 | 2025 | |
| Novo Nordisk INC | $66.31 | 2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $61.27 | 2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $60.28 | 2025 | Shingrix |
| Lilly USA, LLC | $46.88 | 2025 | Mounjaro, Zepbound |
| Abbvie INC. | $33.29 | 2025 | |
| Verona Pharma, INC. | $23.39 | 2025 | Ohtuvayre |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.64 | 2025 | Caplyta |
| Daiichi Sankyo INC. | $22.22 | 2024 | Injectafer |
| Gilead Sciences, INC. | $22.03 | 2024 | |
| Shield Therapeutics INC | $17.45 | 2025 | |
| Lundbeck LLC | $14.94 | 2024 | Rexulti |
| Amgen INC. | $13.47 | 2025 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandeep Kataria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.